Beraprost injection - United Therapeutics

Drug Profile

Beraprost injection - United Therapeutics

Alternative Names: Beraprost Transcon; Transcon Beraprost

Latest Information Update: 16 Jun 2014

Price : $50

At a glance

  • Originator Toray
  • Developer Ascendis Pharma; United Therapeutics Corporation
  • Class 3-ring heterocyclic compounds; Alkynes; Antiplatelets; Benzofurans; Butyric acids; Cyclopentanes; Prostaglandins; Small molecules; Vasodilators
  • Mechanism of Action Prostacyclin agonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No

Highest Development Phases

  • Phase Unknown Pulmonary arterial hypertension

Most Recent Events

  • 30 Sep 2012 Investigation in Pulmonary arterial hypertension in USA (SC)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top